Results 321 to 330 of about 4,480,665 (367)
Some of the next articles are maybe not open access.
Journal of the American Medical Association, 1958
Administration of effective doses of iron in the treatment of iron deficiency anemia is complicated by the fact that iron compounds are not innocuous. Toxicity experiments on dogs and rabbits are here summarized; they showed that the concentration of iron attained in the animal's serum determined the severity of the acute symptoms.
W G Rohse +3 more
openaire +3 more sources
Administration of effective doses of iron in the treatment of iron deficiency anemia is complicated by the fact that iron compounds are not innocuous. Toxicity experiments on dogs and rabbits are here summarized; they showed that the concentration of iron attained in the animal's serum determined the severity of the acute symptoms.
W G Rohse +3 more
openaire +3 more sources
Chelation Therapy of Atherosclerosis
Drug Intelligence & Clinical Pharmacy, 1984Chelation therapy with intravenous injections of edetate disodium is being promoted to the public as a nonsurgical means to treat coronary or other arterial atherosclerosis. The rationale for use, clinical efficacy, and safety are reviewed. Acceptable evidence supporting chelation therapy for atherosclerotic vascular disease is lacking.
Larry K. Golightly, Kaye L. Rathmann
openaire +3 more sources
Clinical toxicology, 2019
Introduction: Gadolinium-based contrast agents are widely used for magnetic resonance imaging and, until recently, had been generally considered to have an excellent safety profile in patients with normal renal function.
K. Layne, D. Wood, P. Dargan
semanticscholar +1 more source
Introduction: Gadolinium-based contrast agents are widely used for magnetic resonance imaging and, until recently, had been generally considered to have an excellent safety profile in patients with normal renal function.
K. Layne, D. Wood, P. Dargan
semanticscholar +1 more source
Combined iron chelation therapy
Annals of the New York Academy of Sciences, 2010Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications. Despite the availability of three iron chelators, some patients fail to respond adequately to monotherapy with any of them. Combination therapy, consisting in the use of two
Galanello Renzo +5 more
openaire +3 more sources
2002
Although iron chelation therapy with deferoxamine (DFO) has changed life expectancy in thalassemic patients, compliance with the rigorous requirements of long-term subcutaneous DFO infusions is unsatisfactory. This problem underlines the current efforts for developing alternative, orally effective chelators to improve compliance and treatment results ...
Chaim Hershko +3 more
openaire +3 more sources
Although iron chelation therapy with deferoxamine (DFO) has changed life expectancy in thalassemic patients, compliance with the rigorous requirements of long-term subcutaneous DFO infusions is unsatisfactory. This problem underlines the current efforts for developing alternative, orally effective chelators to improve compliance and treatment results ...
Chaim Hershko +3 more
openaire +3 more sources
Chelation Therapy for Arteriosclerosis
JAMA: The Journal of the American Medical Association, 1975SOME profess that a certain intravenously administered colorless compound is the elixir of youth. Chelation therapy with edetate disodium (EDTA) solution is described in tones of evangelical fervor in a brochure from a medical clinic: Chelation therapy for hardening of the arteries is a special treatment given by licensed medical doctors for the ...
openaire +3 more sources
Current Opinion in Hematology, 1995
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
ChemInform Abstract: Chelation Therapy for Neurodegenerative Diseases
ChemInform, 2009AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Bolognin S +3 more
openaire +6 more sources
Iron chelators in cancer therapy
BioMetals, 2020Iron chelators have long been a target of interest as anticancer agents. Iron is an important cellular resource involved in cell replication, metabolism and growth. Iron metabolism is modulated in cancer cells reflecting their increased replicative demands.
Ola Ibrahim, Jeff O’Sullivan
openaire +3 more sources
Reviews in Clinical and Experimental Hematology, 2000
In chronic anemias associated with iron overload, iron chelation therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for the treatment of transfusional iron overload since the early 1960s, the era of modern and effective iron chelation ...
A. Victor Hoffbrand, Chaim Hershko
openaire +2 more sources
In chronic anemias associated with iron overload, iron chelation therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Although desferrioxamine (DFO) has been available for the treatment of transfusional iron overload since the early 1960s, the era of modern and effective iron chelation ...
A. Victor Hoffbrand, Chaim Hershko
openaire +2 more sources